The Global Healthcare Bioconvergence Market size is expected to reach $169.9 billion by 2028, rising at a market growth of 7.0% CAGR during the forecast period.
Bioconvergence is an all-encompassing strategy that addresses many biotech chain links, including bioprinting, biomimicry, omics, and diagnostics. By combining biology with several engineering disciplines like nanotechnology, physics, computer science, advanced genetic engineering, artificial intelligence, material science, and electronics, this process is known as bio convergence.
Bioconvergence is a sector of the healthcare and life science research industries that stresses the interdependence of engineering, technology, and computerized systems. The idea behind bioconvergence is that biology and technology, the two cornerstones of biotechnology, aren"t as incompatible as they first appear.
The concept of bioconvergence is not restricted to specific biotech chain phases. It"s a method that can be used from beginning to end. The bioconvergence paradigm is at the foundation of many new fields in biotech, including omics, biomimicry, bioprinting, and diagnostics.
Researchers must produce outstanding advancements in medical research and therapy due to the rising prevalence of chronic diseases afflicting the global population. The race to have a significant influence is on. New cancer therapies, better medications and vaccinations, quick testing and precise diagnosis, better and simpler access to healthcare services via digital means, and so forth.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BiomX, Inc., Singota Solutions, Anima Biotech Inc., Ginkgo Bioworks Holdings, Inc., SetPoint Medical Corporation, Galvani Bioelectronics, Ltd. (GlaxoSmithKline plc and Verily Life Sciences), and BICO Group AB (publ)
Bioconvergence is an all-encompassing strategy that addresses many biotech chain links, including bioprinting, biomimicry, omics, and diagnostics. By combining biology with several engineering disciplines like nanotechnology, physics, computer science, advanced genetic engineering, artificial intelligence, material science, and electronics, this process is known as bio convergence.
Bioconvergence is a sector of the healthcare and life science research industries that stresses the interdependence of engineering, technology, and computerized systems. The idea behind bioconvergence is that biology and technology, the two cornerstones of biotechnology, aren"t as incompatible as they first appear.
The concept of bioconvergence is not restricted to specific biotech chain phases. It"s a method that can be used from beginning to end. The bioconvergence paradigm is at the foundation of many new fields in biotech, including omics, biomimicry, bioprinting, and diagnostics.
Researchers must produce outstanding advancements in medical research and therapy due to the rising prevalence of chronic diseases afflicting the global population. The race to have a significant influence is on. New cancer therapies, better medications and vaccinations, quick testing and precise diagnosis, better and simpler access to healthcare services via digital means, and so forth.
COVID-19 Impact Analysis
The COVID-19 pandemic had a significant influence on medical technology, drug development, and health technology. As a result of reducing the time needed to bring a drug to market by accelerating the discovery of the sequence, virtual selection, and process of validation, AI-based tools enable the prediction of drugs or peptide bonds straight from the genomic sequences of an infectious person. This results in the boost of drugs or vaccine development and advanced technologies. AI and ML technologies have helped in screening, prediction, forecasting, contact tracing, and drug/vaccine development during the ongoing COVID pandemic. The extensive use of COVID-19 has benefited the healthcare biotechnology business as a result of these aspects.Market Growth Factors
Industry 4.0 has created a new paradigm for the industrial sector.
Similarly to manufacturing, the delivery of healthcare is about to undergo a fundamental shift into a new era of connected, smart healthcare. Industry 4.0 and the fourth healthcare revolution are currently emerging. In such a situation, the process of providing healthcare transforms into a cyber-physical system outfitted with wearables, RFID (radio-frequency identification), IoT, and various medical devices, medical robots, intelligent sensors, etc., that are incorporated with cloud computing, artificial intelligence, big data analysis, and decision support methods for achieving smart and interconnected healthcare delivery. Therefore, as a result of industry 4.0"s widespread acceptance in the healthcare sector.Bioconvergence As A Source Of Finance For New Businesses
Every industry has specific financial needs and worries, whether they relate to accessibility, available channels, investor kinds, or investment size. The locations of such start-ups are frequently based on the availability of funding. For medical and life science start-ups, access to funding for research (long-term ROI on higher-than-average investments) is a major challenge.Market Restraining Factors
Rising Data Privacy Concerns Because Of Ai Implementation In Healthcare
There are several practical uses for AI in the medical field. However, due to worries about data protection, AI use in the sector is constrained. In several nations, patient health data is protected by federal regulations, and any violations or failures to maintain its integrity may result in monetary and legal consequences. Since patient care utilizing AI necessitates access to numerous health datasets, AI-based technologies must follow all data security regulations put in place by regulatory and governmental bodies. The market for healthcare bioconvergence is severely constrained by this problem.Application Outlook
Based on applications, the market is classified into drug discovery, nano-robotics for drug delivery, regenerative medicine, diagnostic & biological sensor, bioelectronics, engineered living materials, optogenetics, precision medicine, and standalone. A new strategy called precision medicine (PM) gives the idea that it will alter the way that medicine is now practiced. Modern healthcare is being transformed by the IoT movement, which offers promising technological, economic, and societal prospects. The IoT, whose usage in PM is increasing, can be integrated to further strengthen the function that PM performs. Such increasing utilization of IoT in PM will aid in the growth of the bioconvergence market in healthcare.
Regional Outlook
Based on geography, the market is classified in North America, Europe, Asia Pacific, and LAMEA. In 2021, the Europe market gained the largest revenue share in the healthcare bioconvergence market as the region is home to prestigious research institutions, medical facilities, and hospitals that provide a solid foundation for identifying and developing cutting-edge scientific and medical therapies. The market is primarily driven by the highly developed healthcare sector and the prevalence of cutting-edge healthcare infrastructure in nations including the U.K., France, and Germany, among others.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BiomX, Inc., Singota Solutions, Anima Biotech Inc., Ginkgo Bioworks Holdings, Inc., SetPoint Medical Corporation, Galvani Bioelectronics, Ltd. (GlaxoSmithKline plc and Verily Life Sciences), and BICO Group AB (publ)
Scope of the Study
By Application
- Drug Discovery
- Precision Medicine
- Regenerative Medicine
- Diagnostic & Biological Sensors
- Bioelectronics
- Nanorobotics for Drug Delivery
- Engineered Living Materials
- Optogenetics
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- BiomX, Inc.
- Singota Solutions
- Anima Biotech Inc.
- Ginkgo Bioworks Holdings, Inc.
- SetPoint Medical Corporation
- Galvani Bioelectronics, Ltd. (GlaxoSmithKline plc and Verily Life Sciences)
- BICO Group AB (publ)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Healthcare Bioconvergence Market, by Application
1.4.2 Global Healthcare Bioconvergence Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Healthcare Bioconvergence Market by Application
3.1 Global Drug Discovery Market by Region
3.2 Global Precision Medicine Market by Region
3.3 Global Regenerative Medicine Market by Region
3.4 Global Diagnostic & Biological Sensors Market by Region
3.5 Global Bioelectronics Market by Region
3.6 Global Nanorobotics for Drug Delivery Market by Region
3.7 Global Engineered Living Materials Market by Region
3.8 Global Optogenetics Market by Region
Chapter 4. Global Healthcare Bioconvergence Market by Region
4.1 North America Healthcare Bioconvergence Market
4.1.1 North America Healthcare Bioconvergence Market by Application
4.1.1.1 North America Drug Discovery Market by Country
4.1.1.2 North America Precision Medicine Market by Country
4.1.1.3 North America Regenerative Medicine Market by Country
4.1.1.4 North America Diagnostic & Biological Sensors Market by Country
4.1.1.5 North America Bioelectronics Market by Country
4.1.1.6 North America Nanorobotics for Drug Delivery Market by Country
4.1.1.7 North America Engineered Living Materials Market by Country
4.1.1.8 North America Optogenetics Market by Country
4.1.2 North America Healthcare Bioconvergence Market by Country
4.1.2.1 US Healthcare Bioconvergence Market
4.1.2.1.1 US Healthcare Bioconvergence Market by Application
4.1.2.2 Canada Healthcare Bioconvergence Market
4.1.2.2.1 Canada Healthcare Bioconvergence Market by Application
4.1.2.3 Mexico Healthcare Bioconvergence Market
4.1.2.3.1 Mexico Healthcare Bioconvergence Market by Application
4.1.2.4 Rest of North America Healthcare Bioconvergence Market
4.1.2.4.1 Rest of North America Healthcare Bioconvergence Market by Application
4.2 Europe Healthcare Bioconvergence Market
4.2.1 Europe Healthcare Bioconvergence Market by Application
4.2.1.1 Europe Drug Discovery Market by Country
4.2.1.2 Europe Precision Medicine Market by Country
4.2.1.3 Europe Regenerative Medicine Market by Country
4.2.1.4 Europe Diagnostic & Biological Sensors Market by Country
4.2.1.5 Europe Bioelectronics Market by Country
4.2.1.6 Europe Nanorobotics for Drug Delivery Market by Country
4.2.1.7 Europe Engineered Living Materials Market by Country
4.2.1.8 Europe Optogenetics Market by Country
4.2.2 Europe Healthcare Bioconvergence Market by Country
4.2.2.1 Germany Healthcare Bioconvergence Market
4.2.2.1.1 Germany Healthcare Bioconvergence Market by Application
4.2.2.2 UK Healthcare Bioconvergence Market
4.2.2.2.1 UK Healthcare Bioconvergence Market by Application
4.2.2.3 France Healthcare Bioconvergence Market
4.2.2.3.1 France Healthcare Bioconvergence Market by Application
4.2.2.4 Russia Healthcare Bioconvergence Market
4.2.2.4.1 Russia Healthcare Bioconvergence Market by Application
4.2.2.5 Spain Healthcare Bioconvergence Market
4.2.2.5.1 Spain Healthcare Bioconvergence Market by Application
4.2.2.6 Italy Healthcare Bioconvergence Market
4.2.2.6.1 Italy Healthcare Bioconvergence Market by Application
4.2.2.7 Rest of Europe Healthcare Bioconvergence Market
4.2.2.7.1 Rest of Europe Healthcare Bioconvergence Market by Application
4.3 Asia Pacific Healthcare Bioconvergence Market
4.3.1 Asia Pacific Healthcare Bioconvergence Market by Application
4.3.1.1 Asia Pacific Drug Discovery Market by Country
4.3.1.2 Asia Pacific Precision Medicine Market by Country
4.3.1.3 Asia Pacific Regenerative Medicine Market by Country
4.3.1.4 Asia Pacific Diagnostic & Biological Sensors Market by Country
4.3.1.5 Asia Pacific Bioelectronics Market by Country
4.3.1.6 Asia Pacific Nanorobotics for Drug Delivery Market by Country
4.3.2 Asia Pacific Engineered Living Materials Market by Country
4.3.2.1 Asia Pacific Optogenetics Market by Country
4.3.3 Asia Pacific Healthcare Bioconvergence Market by Country
4.3.3.1 China Healthcare Bioconvergence Market
4.3.3.1.1 China Healthcare Bioconvergence Market by Application
4.3.3.2 Japan Healthcare Bioconvergence Market
4.3.3.2.1 Japan Healthcare Bioconvergence Market by Application
4.3.3.3 India Healthcare Bioconvergence Market
4.3.3.3.1 India Healthcare Bioconvergence Market by Application
4.3.3.4 South Korea Healthcare Bioconvergence Market
4.3.3.4.1 South Korea Healthcare Bioconvergence Market by Application
4.3.3.5 Singapore Healthcare Bioconvergence Market
4.3.3.5.1 Singapore Healthcare Bioconvergence Market by Application
4.3.3.6 Malaysia Healthcare Bioconvergence Market
4.3.3.6.1 Malaysia Healthcare Bioconvergence Market by Application
4.3.3.7 Rest of Asia Pacific Healthcare Bioconvergence Market
4.3.3.7.1 Rest of Asia Pacific Healthcare Bioconvergence Market by Application
4.4 LAMEA Healthcare Bioconvergence Market
4.4.1 LAMEA Healthcare Bioconvergence Market by Application
4.4.1.1 LAMEA Drug Discovery Market by Country
4.4.1.2 LAMEA Precision Medicine Market by Country
4.4.1.3 LAMEA Regenerative Medicine Market by Country
4.4.1.4 LAMEA Diagnostic & Biological Sensors Market by Country
4.4.1.5 LAMEA Bioelectronics Market by Country
4.4.1.6 LAMEA Nanorobotics for Drug Delivery Market by Country
4.4.1.7 LAMEA Engineered Living Materials Market by Country
4.4.1.8 LAMEA Optogenetics Market by Country
4.4.2 LAMEA Healthcare Bioconvergence Market by Country
4.4.2.1 Brazil Healthcare Bioconvergence Market
4.4.2.1.1 Brazil Healthcare Bioconvergence Market by Application
4.4.2.2 Argentina Healthcare Bioconvergence Market
4.4.2.2.1 Argentina Healthcare Bioconvergence Market by Application
4.4.2.3 UAE Healthcare Bioconvergence Market
4.4.2.3.1 UAE Healthcare Bioconvergence Market by Application
4.4.2.4 Saudi Arabia Healthcare Bioconvergence Market
4.4.2.4.1 Saudi Arabia Healthcare Bioconvergence Market by Application
4.4.2.5 South Africa Healthcare Bioconvergence Market
4.4.2.5.1 South Africa Healthcare Bioconvergence Market by Application
4.4.2.6 Nigeria Healthcare Bioconvergence Market
4.4.2.6.1 Nigeria Healthcare Bioconvergence Market by Application
4.4.2.7 Rest of LAMEA Healthcare Bioconvergence Market
4.4.2.7.1 Rest of LAMEA Healthcare Bioconvergence Market by Application
Chapter 5. Company Profiles
5.1 BiomX, Inc.
5.1.1 Company Overview
5.1.2 Research & Development Expenses
5.2 Galvani Bioelectronics, Ltd. (GlaxoSmithKline plc and Verily Life Sciences)
5.2.1 Company Overview
5.2.2 Financial Analysis
5.2.3 Segmental and Regional Analysis
5.2.4 Research & Development Expenses
5.3 BICO Group AB (publ)
5.3.1 Company Overview
5.3.2 Financial Analysis
5.3.3 Segmental and Regional Analysis
5.3.4 Recent strategies and developments:
5.3.4.1 Partnerships, Collaborations, and Agreements:
5.3.4.2 Acquisition and Mergers:
5.4 Ginkgo Bioworks Holdings, Inc.
5.4.1 Company Overview
5.4.2 Financial Analysis
5.4.3 Research & Development Expenses
5.4.4 Recent strategies and developments:
5.4.4.1 Partnerships, Collaborations, and Agreements:
5.5 Singota Solutions
5.5.1 Company Overview
5.6 Anima Biotech Inc.
5.6.1 Company Overview
5.7 Setpoint Medical Corporation
5.7.1 Company Overview
Companies Mentioned
- BiomX, Inc.
- Singota Solutions
- Anima Biotech Inc.
- Ginkgo Bioworks Holdings, Inc.
- SetPoint Medical Corporation
- Galvani Bioelectronics, Ltd. (GlaxoSmithKline plc and Verily Life Sciences)
- BICO Group AB (publ)
Methodology
LOADING...
